MIR542

Summary

MIR542 (microRNA 542, HGNC:32534) is a microRNA gene on chromosome Xq26.3.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 664617 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32534
Approved symbol	MIR542
Name	microRNA 542
Location	Xq26.3
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-542
Ensembl gene	ENSG00000207784
Ensembl biotype	miRNA
Entrez	664617
RNAcentral	URS000075B0FE — miRNA, 97 nt, 5 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000385050

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000385050 — 1 exons

Exon	Start	End
ENSE00001500057	134541341	134541437

Expression profiles

Bgee: expression breadth broad, 59 present calls, max score 81.07.

Top tissues by expression

59 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endometrium	UBERON:0001295	81.07	gold quality
tibial artery	UBERON:0007610	77.85	gold quality
blood	UBERON:0000178	77.18	gold quality
muscle of leg	UBERON:0001383	75.89	gold quality
right ovary	UBERON:0002118	75.00	gold quality
gastrocnemius	UBERON:0001388	73.84	gold quality
heart	UBERON:0000948	72.65	gold quality
right atrium auricular region	UBERON:0006631	72.64	gold quality
adrenal tissue	UBERON:0018303	71.85	gold quality
intestine	UBERON:0000160	71.55	gold quality
esophagus mucosa	UBERON:0002469	71.25	gold quality
stomach	UBERON:0000945	70.91	gold quality
ovary	UBERON:0000992	70.29	gold quality
left adrenal gland	UBERON:0001234	69.96	gold quality
urinary bladder	UBERON:0001255	69.95	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	69.95	gold quality
left ovary	UBERON:0002119	69.81	gold quality
body of stomach	UBERON:0001161	69.25	gold quality
myometrium	UBERON:0001296	69.21	gold quality
colon	UBERON:0001155	68.63	gold quality
ascending aorta	UBERON:0001496	68.27	gold quality
heart left ventricle	UBERON:0002084	68.20	gold quality
lower esophagus muscularis layer	UBERON:0035833	67.77	gold quality
body of pancreas	UBERON:0001150	67.08	gold quality
omental fat pad	UBERON:0010414	66.76	gold quality
spleen	UBERON:0002106	66.40	gold quality
transverse colon	UBERON:0001157	66.16	gold quality
Brodmann (1909) area 9	UBERON:0013540	65.88	gold quality
left uterine tube	UBERON:0001303	65.56	gold quality
nucleus accumbens	UBERON:0001882	65.55	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.32

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• survivin is a direct target of miR-542. (PMID:20728447)
• Our results suggest that the novel c-Src-miR-542-3p-ILK-FAK circuit plays a crucial role in controlling tumor progression. (PMID:21860426)
• these findings suggest that miR-542-5p may act as an important modulator of EGFR-mediated oncogenesis, with potential applications as a novel therapeutic target in lung cancer. (PMID:22426479)
• The circulating miRNAs miR-199a, miR-122, miR-145*, and miR-542-3p could potentially serve as noninvasive biomarkers for endometriosis. (PMID:23118427)
• Anti-angiogenic miR-542-3p directly targets the key angiogenesis-promoting protein Angpt2 to prevent tumor angiogensis. (PMID:24403060)
• miR-542-3p is an important positive regulator of p53 with potential applications in cancer treatment. (PMID:24762395)
• Downregulating Survivin using siRNA copied the phenotype of miR-542-3p expression in neuroblastoma cell lines, while cDNA-mediated ectopic expression of Survivin partially rescued the phenotype induced by miR-542-3p expression (PMID:25046253)
• The miR5423p regulates the endogenous expression of VANGL2. (PMID:25352048)
• data suggest that miR-542-3p might function as a tumor suppressor in gastric cancer, potentially by targeting the oncogene AEG-1 (PMID:25432696)
• miRNA5423p downregulation may contribute to the trastuzumab resistance in breast cancer via, at least in part, the PI3Kakt pathway. (PMID:25586125)
• Suggest a novel regulatory pathway whereby breast tumor-derived angiogenin directly activates angiogenesis through inhibition of miR-542-3p. (PMID:26272182)
• miR-542-3p acts as a negative regulator in astrocytoma progression and that miR-542-3p down-regulation contributes to aberrant activation of AKT signaling (PMID:26286747)
• miR-542-3p was frequently decreased in human ESCC. MiR-542-3p functioned as a tumor suppressor in ESCC involving in the promotion of cell proliferation (PMID:26323919)
• miR-542-5p plays a critical role in the proliferation of osteosarcoma and targets HUWE1. (PMID:26498360)
• MiR-542-3p and its target gene survivin may play crucial roles in the aggressive progression of human bladder cancer. (PMID:26723509)
• miR-542-3p inhibits the invasion of colorectal cancer cells by targeting CTTN. (PMID:26952924)
• Overexpression of PIM1 partially rescued miR-542-3p-mediated suppression of cell migration, invasion and EMT. Our results collectively indicate that miR-542-3p serves as a metastasis suppressor in melanoma, supporting its utility as a promising therapeutic candidate. (PMID:27107696)
• Taken together, our study suggests that miR-542-3p inhibits HCC cell growth by targeting FZD7 and inhibiting Wnt signaling pathway. The decreased miR-542-3p expression may also contribute to the progression of HCC and may represent a novel molecular therapeutic target for HCC. (PMID:27815069)
• Results suggest that miR-542-3p plays an important role in endometrial decidualization by regulating the expression of major decidual marker genes. (PMID:28051155)
• miR-542-3p functioned as a tumor suppressor gene in regulating the epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma via targeting UBE3C. (PMID:28666208)
• miR-542-3p functions as a suppressor gene by targeting and upregulating FTSJ2, thus inhibiting the malignancy of non-small cell lung cancer cells (PMID:28866101)
• Survival analyses showed that lung cancer patients with lower miR-542-5p levels had markedly poorer prognosis. (PMID:28927388)
• serum miR-542-3p levels could serve as a non-invasive blood biomarker for tumor monitoring and prognostic prediction in osteosarcoma patients. (PMID:29103020)
• Study revealed that upregulation of miR-542-3p suppressed the growth and invasion of colon cancer cells through PI3K/AKT/surviving signaling. (PMID:29130099)
• miR-542-3p have a strong inhibitory effect on the proliferation of MGC-803 cancer cells in a typical dose dependent manner. (PMID:29181687)
• identified four miRNAs, miR-19, miR-340, miR-374 and miR-542 that bind to the 3’-UTR of the MID1 mRNA. These miRNAs not only regulate MID1 expression but also mTOR signaling and translation of disease associated mRNAs and could therefore serve as potential drugs for future therapy development (PMID:29293623)
• miRNA has-miR-542-5p is associated with tamoxifen resistance and can predict prognosis of breast cancer patients (PMID:29371858)
• Results find that miRNA-542 is significantly downregulated in hepatocellular carcinoma (HCC) cells and tissues and seems to be associated with aggressive clinicopathological characteristics of patients. Moreover, cell assays revealed that miR-542-3p overexpression inhibited HCC cell growth and induced apoptosis. (PMID:29606985)
• These findings showed that miR-542-3p inhibits the proliferation of hepatocellular carcinoma cells by targeting survivin (PMID:29710480)
• Through conducting multivariate analysis in the training test, it was identified that the high expression of hsa-miR-509 and hsa-miR-542 were independent poor prognostic factors, whereas that of hsa-miR-146a and hsa-miR-3667 had a trend to be favorable factors. A 4-miRNA signature was constructed by these miRNAs considering the weight of each. (PMID:30242879)
• MIR-542-3p functions as a tumor-suppressive miRNA in ovarian cancer by directly targeting CDK14. (PMID:30557834)
• Expression of miR5423p in osteosarcoma with miRNA microarray data, and its potential signaling pathways have been reported. (PMID:30569116)
• Quadriceps miR-542-3p and -5p are elevated in COPD and reduce function by inhibiting ribosomal and protein synthesis. (PMID:30676868)
• this study shows that downregulation of miR-542-3p contributes to apoptosis resistance in dermal fibroblasts from systemic sclerosis patients via survivin overexpression (PMID:31066253)
• Long non-coding RNA CASC15 favors tumorigenesis and development of ovarian cancer via sponging miR-542-3p. (PMID:31355601)
• MicroRNA5423p represses OTUB1 expression to inhibit migration and invasion of esophageal cancer cells. (PMID:31939620)
• Role of miRNA-542-5p in the tumorigenesis of osteosarcoma. (PMID:32105410)
• Long noncoding RNA SNHG8 promotes the proliferation of osteosarcoma cells by downregulating miR-542-3p. (PMID:32450677)
• MiR-542-3p drives renal fibrosis by targeting AGO1 in vivo and in vitro (PMID:32470449)
• Long noncoding RNA LINC00963 induces NOP2 expression by sponging tumor suppressor miR-542-3p to promote metastasis in prostate cancer. (PMID:32554858)

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
mus_musculus	Mir542	ENSMUSG00000076140

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.